Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.65 |
| ▸ | CHRNA10 | Q9GZZ6 | 4/20 | 0.65 |
| ▸ | CHRNA9 | Q9UGM1 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4400727 | 0.80 | CHRNA7 (0.68) | CHRNA7CHRNA10CHRNA9LMNAKDM4E | |
| SCHEMBL4400723 | 0.79 | CHRNA7 (0.46) | CHRNA7CHRNA10CHRNA9LMNAPABPC1 | |
| SCHEMBL4401604 | 0.79 | CHRNA7 (1.00) | CHRNA7CHRNA10CHRNA9 | |
| SCHEMBL13334215 | 0.79 | CHRNA7 (0.67) | CHRNA7CHRNA10CHRNA9LMNAKDM4E | |
| Bromide SCHEMBL3312133 | 0.78 | CHRNA7 (0.68) | CHRNA7CHRNA10CHRNA9LMNAKDM4E | |
| SCHEMBL4400684 | 0.77 | CHRNA7 (0.88) | CHRNA7CHRNA10CHRNA9LMNAKDM4E | |
| SCHEMBL13385214 | 0.72 | PABPC1 (0.44) | LMNAKDM4EALDH1A1PABPC1KMT2A | |
| SCHEMBL4404405 | 0.70 | LMNA (0.62) | LMNAKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL12638052 | 0.69 | CHRNA7 (0.68) | CHRNA7CHRNA10CHRNA9LMNAKDM4E | |
| SCHEMBL6114658 | 0.68 | PABPC1 (0.50) | LMNAKDM4EALDH1A1PABPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160340335-A9 | METHOD OF TREATING NEUROPATHIC PAIN | UNIVERSITY OF UTAH (US) | 2016-11-24 | — | — | US | disclosed |
| US-9499518-B2 | Bis-quaternary ammonium salts as pain modulating agents | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2016-11-22 | — | — | US | disclosed |
| US-20140011836-A1 | METHOD OF TREATING NEUROPATHIC PAIN | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-01-09 | — | — | US | disclosed |
| US-8178678-B2 | Bis-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100069432-A1 | Bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340335-A9 | METHOD OF TREATING NEUROPATHIC PAIN | INA, GAP43, ACHE | CHRNA7 157/4885CHRNA10 126/4885CHRNA9 233/4885 |
| US-20100069432-A1 | Bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | CHRNA2, CHRNA5, CHRNA4 | CHRNA7 7/4885CHRNA10 4/4885CHRNA9 12/4885 |
| US-20140011836-A1 | METHOD OF TREATING NEUROPATHIC PAIN | INA, GAP43, ACHE | CHRNA7 157/4885CHRNA10 126/4885CHRNA9 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.